Deutsches Primatenzentrum (DPZ), Leibniz-Institut für Primatenforschung

Lung cell entry, cell-cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75 (2022) Arora P, Nehlmeier I, Kempf A, Cossmann A, Schulz S, Dopfer-Jablonka A, Baier E, et al. Journal article Downregulation of the vitamin D receptor expression during acute gastrointestinal graft versus host disease is associated with poor outcome after allogeneic stem cell transplantation (2022) Matos C, Mamilos A, Shah PN, Meedt E, Weber D, Ghimire S, Hiergeist A, et al. Journal article Protective mucosal immunity against SARS-CoV-2 after heterologous systemic RNA-mucosal adenoviral vector immunization (2022) Lapuente D, Fuchs J, Willar J, Antao A, Eberlein V, Uhlig N, Issmail L, et al. Conference contribution SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies (2022) Arora P, Zhang L, Krüger N, Rocha C, Sidarovich A, Schulz S, Kempf A, et al. Journal article Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant (2022) Arora P, Kempf A, Nehlmeier I, Schulz S, Cossmann A, Stankov MV, Jäck HM, et al. Journal article, Letter Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5 (2022) Arora P, Kempf A, Nehlmeier I, Schulz S, Cossmann A, Stankov MV, Jäck HM, et al. Journal article Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3 (2022) Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A, Schulz S, Cossmann A, et al. Journal article Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2 (2022) Arora P, Kempf A, Nehlmeier I, Graichen L, Schulz S, Cossmann A, Dopfer-Jablonka A, et al. Journal article, Editorial SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination (2022) Arora P, Kempf A, Nehlmeier I, Graichen L, Winkler MS, Lier M, Schulz S, et al. Journal article Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy (2022) Hoffmann M, Sidarovich A, Arora P, Krueger N, Nehlmeier I, Kempf A, Graichen L, et al. Journal article